

OPEN

PIC&RUN: An integrated assay for the detection and retrieval of single viable circulating tumor cells

Mohamed Kamal^{1,2,3}, Shahin Saremi^{1,2,4}, Remi Klotz^{1,2}, Oihana Iriondo^{1,2}, Yonatan Amzaleg^{1,2}, Yvonne Chairez^{1,2}, Varsha Tulpule^{2,5}, Julie E. Lang^{2,6}, Irene Kang^{2,5} & Min Yu^{1,2*}

Circulating tumor cells (CTCs) shed from solid tumors can serve as a minimally invasive liquid biopsy for monitoring disease progression. Because CTCs are rare and heterogeneous, their biological properties need to be investigated at the single cell level, which requires efficient ways to isolate and analyze live single CTCs. Current methods for CTC isolation and identification are either performed on fixed and stained cells or need multiple procedures to isolate pure live CTCs. Here, we used the AccuCyte-RareCyte system to develop a Protocol for Integrated Capture and Retrieval of Ultra-pure single live CTCs using Negative and positive selection (PIC&RUN). The positive selection module of PIC&RUN identifies CTCs based on detection of cancer surface markers and exclusion of immune markers. Combined with a two-step cell picking protocol to retrieve ultrapure single CTCs, the positive selection module is compatible for downstream single cell transcriptomic analysis. The negative selection module of PIC&RUN identifies CTCs based on a live cell dye and the absence of immune markers, allowing retrieval of viable CTCs that are suitable for *ex vivo* culture. This new assay combines the CTC capture and retrieval in one integrated platform, providing a valuable tool for downstream live CTC analyses.

Cancer is one of the leading causes of death worldwide and the majority of these mortalities are caused by distant metastases¹. Hematogenous metastasis is a multi-step process that requires the entry of cancer cells from the primary tumor into the circulation, making circulation the interface between the primary tumor and the secondary site of metastasis². Circulating tumor cells (CTCs) present in the bloodstream contain the seeds of metastasis and are considered a valuable minimally invasive liquid biopsy for solid tumors^{3–6}. Molecular and functional characterization of CTCs will lead to a better understanding of metastasis and facilitate the identification of treatments that most effectively target the evolving solid tumors.

Compared to normal blood cells, CTCs are rare—usually a single digit number of CTCs is present in one milliliter (ml) of blood that also contains 10 million white blood cells (WBCs) and one billion red blood cells (RBCs). Many technologies have been developed for the identification and enumeration of CTCs^{7–15} (reviewed in¹⁶). These technologies enrich CTCs based on their unique physical, morphological and biological properties. Identified CTCs are typically validated by assessing mRNA or protein expression of cancer specific markers on fixed cells, which does not allow expansion of CTCs for further downstream studies.

Although technically challenging, a number of promising technologies have been developed to isolate viable CTCs^{10,17–20}. The recently reported microfluidic technology, CTC-iChip, can efficiently deplete normal blood cells, enables the sorting of viable CTCs in solution²¹, and allowed the *ex vivo* culture of CTCs from 6 breast cancer patients²². Sufficient amount of material from these cultured CTCs enabled RNA sequencing, mutation detection, tumorigenicity analysis, as well as drug sensitivity tests. This study shows that culturing CTCs from patients provides an opportunity to study tumor biology and drug susceptibility that is unique to individual patient²².

In addition, since CTCs can contain tumor cells shed from multiple active tumor lesions, they have the potential to help address the complexity of intra-patient tumor heterogeneity. It has been shown that CTCs present a

¹Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, 90033, USA. ²USC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, California, 90033, USA. ³Department of Zoology, Faculty of Science, University of Benha, Benha, Egypt. ⁴MS Biotechnology program, California State University Channel Islands, Camarillo, CA, 93012, USA. ⁵Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California, 90033, USA. ⁶Department of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California, 90033, USA. *email: minyu@med.usc.edu




Figure 1. Development of PIC&RUN system. (a) An illustration of the PIC&RUN assay. A tube of 7.5 ml blood was processed via AccuCyte and the buffy coat was collected. Based on the planned downstream analyses, either positive or negative selection was used. Positive selection is compatible with single cell RNA sequencing analysis, whereas negative selection is compatible with *ex vivo* culture of single CTCs. (b) CTC detection based on positive or negative selection methods. Left image is a field of view of a buffy coat processed by positive selection approach with IM antibodies (red) and EpCAM antibodies (magenta). A CTC is defined as a cell with IM⁻/EpCAM⁺ (arrow). Right image is a field of view of a buffy coat processed by negative selection approach with IM antibodies (red) and Cell-Tracker green (green). A CTC is defined as a cell with IM⁻/Cell-Tracker green⁺ (arrow).

high degree of heterogeneity in their mutational and transcriptional profiles, as well as physical status of single cells or clusters^{23–33}. Understanding CTC heterogeneity will have a profound impact on our understanding of the mechanisms of metastasis and treatment resistance. However, to unravel such heterogeneity, we need to have the tools to efficiently isolate viable CTCs individually in order to molecularly and functionally characterize them at a single cell level.

Currently, to isolate single live CTCs, additional purification steps, such as the DEPArray^{34,35}, Fluidigm C1^{36–39}, ALS cell-Selector⁴⁰ or single-cell micro-manipulation, are typically used. These procedures often require additional live staining for cancer cell surface markers (CSMs), such as EpCAM, HER2 and EGFR²³, which enable pure CTCs to be retrieved for single cell RNA-sequencing analysis^{34,36,37}. However, these additional steps may lead to CTC loss and can be time-consuming. In addition, although viable CTCs isolated using these positive live markers are suitable for molecular analyses, they may not be suitable for *ex vivo* culture as the effects of antibodies on cell survival and proliferation are unclear. Therefore, there is a necessity to develop an integrated and unbiased system that allows for the isolation of single viable CTCs for single cell molecular analysis and *ex vivo* expansion.

Recently, the AccuCyte-RareCyte system was described for the identification and isolation of single CTCs. In this method, nucleated cells from a blood sample were collected using the AccuCyte sample preparation system, spread onto slides and stained with cancer cell and WBC specific antibodies. The slides were scanned by a high-speed fluorescence scanner, the CyteFinder. Finally, CTCs were retrieved using the CytePicker module, which uses a needle with a ceramic tip⁴¹. Although it is a very promising approach for the detection and retrieval of single fixed CTCs, it is not suitable for downstream analyses that require live cells.

In this study, we developed a Protocol for Integrated Capture and Retrieval of Ultra-pure single live CTCs using Negative and positive selection (PIC&RUN) based on the AccuCyte-RareCyte system. If transcriptomic analyses are required, samples are processed for the positive selection module based on CSMs, whereas, if *ex vivo* culture and functional analyses are required, samples are processed using negative selection module based on exclusion of the normal blood cell markers (Fig. 1a).

	ExpNo.	No. Spiked CTCs	No. Detected CTCs	CTC capture (%)
	1	165	118	71.5
	2	337	379	112.5
	3	1209	1099	90.9
Average		570	532	91.6
SD				17

Table 1. Capture efficiency of AccuCyte for live CTCs.

	Positive Selection				Negative Selection			
No. Spiked cells	1	1	1	14	1	1	1	24
No. Detected cells	1	1	1	12	1	1	1	24

Table 2. Sensitivity of positive and negative selection approaches for detection of live CTCs.

Results and Discussion

High capture efficiency of live CTCs by accuCyte. First, we used our previously established patient-derived CTC lines²² to test the efficiency of AccuCyte for capturing viable CTCs. CTCs (range between 165–1209) stained with the live stain DiO were spiked into 7.5 ml of blood from healthy volunteers and processed using AccuCyte. DiO positive cells from the buffy coats were counted under a fluorescence phase contrast microscope. Capture efficiency of live CTCs reached an average of 91.6% (Table 1), consistent with the previously reported capture efficiency (more than 90%) for fixed CTCs in AccuCyte-RareCyte system^{41,42}.

Optimization of markers for positive and negative detection of CTCs. We developed two strategies for detecting live CTCs from AccuCyte buffy coats. For both strategies, buffy coats were stained live with a cocktail of antibodies against immune markers (IM) plus either a combination of antibodies against CSMs for the positive selection approach or a live cell dye (LCD) for the negative selection approach.

We tested the sensitivity and specificity of three IM antibodies (CD14, CD16, and CD45), either individually or combined, using buffy coats from healthy volunteers' blood. A cocktail of the three IM antibodies showed positive staining in 100% of immune cells but negative in the BRx68 CTC line (Supplementary Fig. 1).

A previously described antibody cocktail for positive selection includes antibodies against EpCAM, HER2 and EGFR^{23,43}. Notably, all our CTC lines tested (BRx68, BRx07, and BRx50) showed 100% positivity for EpCAM staining. Therefore, we used EpCAM expression and absence of IM signals to detect CTCs from our CTC lines during optimization of this method (Fig. 1b). For negative selection, three LCDs—DiO, Cell-Tracker green and ViaFluor—were tested for optimum concentration, visualization and cell viability. There was no significant difference in cell proliferation between control unstained cells and any of the dyes (Supplementary Fig. 2). We decided to use Cell-Tracker green based on the optimal fluorescence intensity and degree of variability (Supplementary Fig. 3). Therefore, in the negative selection, CTCs were identified based on the lack of IM expression and the presence of Cell-Tracker green staining (Fig. 1b).

Specificity and sensitivity of positive and negative detection protocols. To test the detection rates of both positive and negative selection approaches, spike-in experiments were performed using our EpCAM⁺ CTC lines. In order to confirm the identity of CTCs, we spiked in cells that had been pre-stained with Cell-Tracker green for the positive selection method and EpCAM for the negative selection method. Blood was then processed according to the positive selection or negative selection protocols and stained buffy coats were plated on polyhema-coated cyteslides and scanned semi-automatically using RareCyte fluorescence scanner.

For positive selection, CTCs pre-stained with Cell-Tracker green (ranging from 313 to 695 cells) were spiked into 7.5 ml of blood from healthy volunteers and detected as EpCAM⁺/IM⁻ cells via positive selection protocol with an average of 78% detection rate. We confirmed the identity of the detected CTCs via Cell-Tracker green staining and found that 98% of the detected CTCs are Cell-Tracker green⁺, 2% (9 out of 438) were Cell-Tracker green⁻ (false positive), and 3% (19 out of 560) of the spiked-in cells were EpCAM⁻/IM⁻/Cell-Tracker green⁺ (false negative) (Supplementary Table 1). The discrepancy between these data and our initial testing of AccuCyte detection efficiency of live CTCs may be due to cell loss during the staining procedure or error related to large number of spiked cells. To simulate the rare number of CTCs in patients' blood, Cell-Tracker green pre-stained CTCs were precisely counted on 8 chamber slides and single BRx68, BRx50 or BRx07 cells or 14 pre-stained CTCs (BRx68) were picked using RareCyte needle and spiked into 7.5 ml of blood from healthy volunteers and processed by positive selection method. We were able to detect the single spiked CTCs in three independent experiments and 12/14 CTCs in one experiment, without any false positive or false negative CTCs (Table 2). Identities of the detected CTCs were confirmed by the positive Cell-Tracker green staining (Fig. 2a).

To evaluate the capture rate of the negative selection approach, CTCs were pre-stained with anti-EpCAM antibody. Single or 24 EpCAM⁺ CTCs were precisely picked as mentioned above and spiked into 7.5 ml of healthy volunteers' blood, which was then processed with the negative selection approach. 24 out of 24 CTCs, and single CTCs in three independent experiments were detected (Table 2). All detected CTCs were confirmed through their pre-stained EpCAM signal (Fig. 2a).




Figure 2. Evaluation of the PIC&RUN assay for CTC detection. **(a)** Specificity of the PIC&RUN approach for the detection of CTCs. Left panel shows positive selection module on CTC detection using Cell-Tracker green pre-stained CTCs spiked into healthy volunteers' blood. Identified CTCs are positive for EpCAM staining (Magenta, arrows) and negative for IM staining (red). The third column confirms that the detected CTCs are Cell-Tracker green⁺ (green). Right panel shows negative selection module on CTC detection using EpCAM pre-stained CTCs spiked into healthy volunteers' blood. Identified CTCs are positive for Cell-Tracker green and negative for IM (arrows). The third column confirms that these detected CTCs are EpCAM⁺. **(b)** Isolation of single live CTCs. From left to right: a CTC (arrow) that is positive for Cell-Tracker green (green) and negative for IM (red); the same field of view after picking the CTC; the same CTC after deposition in a glass bottom PCR tube; a CTC after two picks and transferred into 96 well plate.

To evaluate specificity of the negative selection module, 8 blood samples from 3 different healthy volunteers were processed. False positive events were detected in 7 out of 8 blood samples from the three different healthy volunteers ranging from 2 to 6 (Supplementary Table 2). These events may be immune cells with a very weak IM staining or other normal circulating cells. The presence of non-hematologic cells circulating in healthy individuals' blood has been previously reported but not explained^{8,17,44,45}. Thus, CTCs detected by negative selection protocol should be further validated as the case for all other negative depletion based CTC platforms^{21,46–51} or used exclusively for downstream applications that will provide further validation, such as CTC culture or molecular analyses.

Optimization of single live CTC retrieval. Using an interactive manipulation of RareCyte needle, we optimized a protocol for picking single live CTCs from buffy coats, which showed over 80% successful picks with around 100 to 150 WBCs cross contamination in one pick (Fig. 2b). For single cell molecular analyses, it is crucial that CTCs are isolated individually without contaminating immune cells. Ultra-pure single CTCs were successfully retrieved by adding a second pick step (Fig. 2b and Supplementary Fig. 4). This ultra-pure picking protocol provides a capability to retrieve pure single viable CTCs in 0.5 μ L final volume of any buffer or media compatible with downstream studies.

Positive CTC selection is compatible with single cell transcriptomic analyses. We then tested applicability of the positive selection approach for single cell transcriptomic analysis. Cells from three CTC lines (BRx07, BRx50 and BRx68) were spiked into healthy volunteers' blood and processed for CTC identification using positive selection protocol. Three EpCAM⁺/IM⁻ CTCs were picked from each cell line using our two-step picking protocol yielding ultra-pure single CTCs. Three IM⁺/EpCAM⁻ immune cells were also picked individually. Three CTCs from each CTC line were isolated using serial dilution and served as control. Principal Component Analysis (PCA) plots of RNA sequencing data of these single cells showed a clear separation between immune cells and all CTCs, regardless of the isolation procedure (RareCyte vs. serial dilution) (Fig. 3a). Ingenuity Pathway Analysis (IPA) of differentially expressed genes (DEGs) between the isolated CTCs and immune cells showed that the top predicted function of up-regulated genes in CTCs is "cancer" compared to "lymphoid tissue




Figure 3. Single cell RNA sequencing analyses. (a) PCA plot for single CTCs and immune cells identified using positive selection protocol. The CTC population includes cells separated using serial dilution (Control) and cells which were spiked in healthy volunteers' blood and isolated individually using positive selection protocol (processed). (b,c) IPA prediction of functions based on DEGs of upregulated genes in CTCs (b) or immune cells (c). (d) PCA plot for processed Vs. Control CTCs.

structure and development" for the isolated immune cells (Fig. 3b,c). This result further validated the precision of our positive selection protocol and demonstrated that the identified and picked cells are compatible with single cell transcriptomic analysis.

To test if processing through the positive selection protocol influences gene expression profiles, we ran PCA plot for processed versus control CTCs (Fig. 3d). This showed that, our positive detection and retrieval of live CTCs has no obvious effect on the transcriptomes of BRx50 or BRx68 CTC lines. However, processed cells of BRx07 line clustered together away from control cells, suggesting an effect of processing on this cell line. This may attribute to the effect of antibody in this particular line or the possibility that cells may have experienced attack from immune cells from a different individual. This latter issue would not exist in real patient samples.

Negative CTC selection is compatible with CTC *ex vivo* culture. The applicability of negative selection approach for *ex vivo* culture was tested in three independent experiments. CTCs were spiked into healthy donors' blood and processed using the negative selection protocol with Cell-Tracker green as a LCD. In each experiment, a range of 16 to 24 Cell-Tracker green⁺/IM⁻ cells were picked and cultured individually for 3 weeks. Similar numbers of cells were isolated individually using serial dilution and were cultured in parallel to serve as controls. The mean of area under curve (AUC) of single cell clones' proliferation over time in the control group was significantly higher than that in the Cell-Tracker green group (Fig. 4a). This difference is caused by a significant delay in cell proliferation of the cell-Tracker green⁺ cells during the first week of culture. However, their proliferation rates were comparable to control cells at weeks 2 and 3 (Fig. 4b). The delay observed in the Cell-Tracker green group may be a consequence of the handling process or an immune reaction of the healthy volunteers' blood against spiked cells.

Detection and isolation of CTCs from breast cancer patients. We evaluated the performance of the PIC&RUN assay (live CTCs) against the AccuCyte-CyteFinder system (fixed CTCs)⁴² in advanced breast cancer patients' samples. The enumeration of CTCs was assessed in 14 patients using both AccuCyte-CyteFinder and PIC&RUN (negative selection). In 5 of the 14 patients, CTCs were also quantified using PIC&RUN (positive selection). In order to unbiasedly determine the negativity of IM, we quantified the fluorescence of IM staining relative to the background in immune cells and in spiked-in CTCs and determined less than 1.2 as a threshold for the negativity in IM channel (Fig. 5a).

PIC&RUN (Negative selection) showed much higher number of CTC-positive patients and higher CTC counts per patient compared to both AccuCyte-CyteFinder and PIC&RUN (positive selection) (Table 3). Interestingly, in the 5 patients who were tested using the three methods, they were negative using both AccuCyte-CyteFinder and PIC&RUN (positive selection), whereas the PIC&RUN (negative selection) showed 3 out of 5 patients were positive with a range of 4 to 13 CTCs (Table 3). CTCs detected by the AccuCyte-CyteFinder system as well as the PIC&RUN assay varied in size and morphology (Fig. 5b,c). The high CTC numbers detected by negative selection agree with the level of false positive events detected in the healthy volunteers' blood using negative selection as discussed above. This may also indicate the possibility of the presence of CTC's subpopulations beyond the detection window of both the AccuCyte-CyteFinder system (which only detects epithelial CTCs) and




Figure 4. *Ex vivo* culture of single CTCs isolated using negative selection. (a) Area under the curve (AUC) measured for single cell clones over 21 days in CTCs isolated via serial dilution (control) or via negative selection protocol of spiked-in CTCs (Cell-Tracker). (b) Proliferation rates of single cell clones over time from three independent experiments; Mean \pm SEM.




Figure 5. Detection of CTCs in the blood of breast cancer patients. (a) Quantification of the relative fluorescence signal of IM staining in immune cells and spiked-in CTCs. (b) Representative images for CTCs detected in patients using AccuCyte-CyteFinder system. (c) Representative images of CTCs detected and picked using PIC&RUN (negative selection).

the PIC&RUN (positive selection) which detects only CTCs positive for EpCAM, HER2 and/or EGFR. Studies showed that CTCs are heterogeneous and epithelial and mesenchymal CTCs could be present in the blood of the same patient^{23,24,26,52}. Although the number of patients in our study is too small to draw a conclusion, there was a trend of association between CTC counts, measured by PIC&RUN (negative selection), and patients' prognosis. The highest number of CTCs was found in the only patient (BC309) who had a progressing disease under treatment after receiving 5 lines of therapy. The second highest number of CTCs was in a patient (BC305) with the highest number of metastatic organs, despite having stable disease at the time of blood draw (Table 3).

Patient ID	Age at diagnosis	ER/PR/HER2 Status	Disease Status at time of blood draw	Disease Status at last visit	Days from blood draw to last visit	Lines of Treatment	Metastatic sites	CTC counts in 7.5 ml of blood		
								AccuCyte-Cytefinder	PIC&RUN	
									Negative selection	Positive selection
BC299	45	ER ⁻ /PR ⁻ /HER2 ⁻	NA	CR ^l	154	1	NA	0	3	NA
BC303	61	ER ⁺ /PR ⁺ /HER2 ⁻	SD	SD ^{tt}	121	1	Bone	0	3	NA
BC304	50	ER ⁻ /PR ⁻ /HER2 ⁺	SD	PD ^{ttt}	119	3	Sternum, LN*, chest wall	0	3	NA
BC305	53	ER ⁻ /PR ⁻ /HER2 ⁺	SD	NA	70	1	Bone, LN, chest wall, lung, skin, muscle invasion	14	17	NA
BC306	31	ER ⁺ /PR ⁺ /HER2 ⁻	SD	SD	107	1	Bone	0	6	NA
BC307	63	ER ⁺ /PR ⁺ /HER2 ⁻	SD	SD	93	1	Bone, pleura, LN	2	5	NA
BC308	58	ER ⁺ /PR ⁺ /HER2 ⁻	SD	SD	63	1	Bone	0	4	NA
BC309	54	ER ⁻ /PR ⁻ /HER2 ⁺	PD	PD	56	5	Breast, LN, skin, brain	4	24	NA
BC310	47	ER ⁻ /PR ⁻ /HER2 ⁻	NA	NA	23	0	LN, Skin, chest wall, pleural effusion	0	4	NA
BC311	44	ER ⁺ /PR ⁺ /HER2 ⁻	SD	SD	0	1	Visceral- liver, lungs	0	13	0
BC312	66	ER ⁺ /PR ⁺ /HER2 ^{**}	SD	SD	0	1	Bone	0	0	0
BC314	48	ER ⁺ /PR ⁺ /HER2 ⁻	SD	CR	30	1	LN	0	4	0
BC315	52	ER ⁻ /PR ⁻ /HER2 ⁺	PR ^{tttt}	SD	21	1	Skin, LN	0	0	0
BC316	39	ER ⁺ /PR ⁺ /HER2 ⁻	SD	SD	1	1	Gastric, ovaries, fallopian tube, cervix	0	12	0

Table 3. CTC counts using AccuCyte-CyteFinder and PIC&RUN in breast cancer patients. *LN = lymph node. ** = equivocal. ^lCR = complete response, ^{tt}SD = stable disease, ^{ttt}PD = progressive disease, ^{tttt}PR = partial response.

In conclusion, our PIC&RUN approach is a novel assay for the detection and isolation of live single CTCs with two modules (positive and negative selections), allowing downstream single cell transcriptomic analyses and *ex vivo* culture of single CTCs. The limitation of our protocol is the relatively long processing time (due to semi-automatic scanning) which allows us to process up to two patient samples per day compared to 20 samples using the CD45 auto-magnetic-activated cell sorting (MACS) depletion protocol⁴⁶. Although the semi-automatic scanning for CTCs in this assay allows for a precise adjustment of the focus for every scanned field, getting this approach fully automated may save time and efforts. Due to a long processing time and relatively more false positive events in the negative selection mode than positive-selection based methods, it is not suitable at current stage for CTC enumeration solely, but rather for research purposes, such as single cell molecular analysis or *ex vivo* culture, which can further confirm the CTC identity afterwards. Future incorporation of validated surface markers for other potential non-hematopoietic, non-tumor cells that have been reported in cancer patients, such as endothelial cells⁵³ or mesenchymal cells⁵⁴, may further improve the specificity. Despite these limitations, the PIC&RUN (negative selection) assay has a high capture efficiency comparable to or higher than other CD45 depletion methods such as CTC-iChip (97%)²¹, the microfluidic NegCTC- μ Chip (83.1%)⁴⁷, deterministic lateral displacement microfluidic structure with MACS (85.1%)⁴⁸, Myltenyi-anti-CD45 microbeads (24%)⁴⁹, Dynabeads-anti-CD45 (97%)⁴⁹, and CanPatrolTM (80%)⁵⁰, spiral microfluidics (80%)⁵¹ and autoMACS (70–88%)⁴⁶. Moreover, PIC&RUN showed a high sensitivity, being able to detect one cell in 7.5 ml of blood. Using a 2-steps picking procedure, PIC&RUN can reach purity at the single cell resolution—the only method thus far detecting and isolating single viable CTCs in one platform.

Methods

Patient samples. A total of 14 breast cancer patients (Stages III and IV) and 3 healthy volunteers were enrolled. Blood samples were collected from all subjects at either Los Angeles-County + University of Southern California (USC) Medical Center or the USC Norris Comprehensive Cancer Center. All experiments were performed in accordance with protocol No. 1B-11-1 approved by the institutional review board at USC. Informed consents were obtained from all participants and/or their legal guardian/s. Approximately 2 × 10 ml of blood was collected (after discarding the first few mls of blood to avoid cross contamination from skin or blood vessels' cells from venipuncture).

Cell culture and spike-in experiments. We have previously established 6 breast cancer patient derived CTC lines²². In this study we used the CTC lines BRx68, BRx50 and BRx07 for all spike-in experiments and immunofluorescence (IF) staining optimization. CTC lines were maintained in RPMI 1640 media (Gibco) supplemented with EGF (20 ng/ml) (Peprotech), basic FGF (20 ng/ml) (Peprotech), B27 (10 ml), and Antibiotic-antimycotic (Life Technologies), in 24 well ultralow attachment tissue culture plates (Corning) at 37 °C, 5% CO₂ and 4% O₂. For spiking low numbers of cells, CTCs were fluorescently labeled live with either DiO (ThermoFisher Scientific), Cell-Tracker green (ThermoFisher Scientific), ViaFluor (Biotium) or antibody against EpCAM, and drawn into 8 chamber glass slides (VWR). Single, 14 or 24 cells were picked using RareCyte needle,

deposited into an 8 chamber slide containing fresh media, and collected and spiked into the blood. Slides were rescanned for left over cells to confirm that the precise number of cells was spiked into the blood. For capture efficiency experiments using large numbers of cells, GFP or DiO positive CTCs were counted using hemocytometer slide and the volume of media containing the required numbers of cells was calculated.

CTC enrichment using AccuCyte. Blood samples were processed using AccuCyte as previously described⁴¹. Briefly, 7.5 ml of blood was added to each AccuCyte Separation Tube (RareCyte) and tubes were centrifuged at 3000 g for 25 minutes (min). After centrifugation, a brass ring clamp (CyteSeal) was applied using a CyteSealer (RareCyte) to each tube. Plasma was then aspirated and 4 ml of displacement solution (RareCyte) was added to each tube. An EpiCollector (RareCyte) with an isolation tube pre-filled with 160 μ L of isolation buffer (RareCyte) was placed on the top of each separation tube. The whole system was centrifuged for 20 min at 1000 g (ThermoFisher Scientific) and buffy coats were then collected into either 800 μ L transfer fluid containing a non-formalin fixative (RareCyte) or 1 ml of CTC media and transferred to 1.8 ml eppendorf tubes for further investigation. Buffy coats resuspended in transfer fluid are kept at RT for 10 min then were spread on glass slides (8 slides per blood sample). Prepared slides were air dried for 30 minutes and stored in -20°C until the day of staining.

Detection of CTCs using AccuCyte-CyteFinder system. Slides were fluorescently stained with the 4D staining kit (RareCyte) which contains antibodies against cytokeratin, EpCAM, and CD45 plus DAPI using the automated staining instrument (BOND RXm, Leica Biosystem). Stained slides were automatically scanned using the fluorescence platform of the RareCyte and images were captured at 10x objective magnification. Slide images were analyzed with integrated image analysis software that automatically analyzes the images to find cytokeratin and/or EpCAM positive cells which are CD45 negative.

Positive selection staining. Buffy coats obtained from AccuCyte diluted in 1 ml of media were stained with a cocktail of PE-CF594 conjugated antibodies against IM and a cocktail of AlexaFluor647 conjugated antibodies against CSMs for 30 min at 37°C . The IM antibody cocktail included anti-CD45, anti-CD14 and anti-CD16 antibodies (BD Biosciences) at a dilution of 1 in 20. CSM antibody cocktail in spike in experiments is anti-EpCAM (Cell Signaling) at a dilution of 1 in 100, whereas in patients' samples anti-HER2 (Biolegend) and anti-EGFR (Biolegend) antibodies were added to the cocktail. Cells were then transferred to 50 ml Falcon tubes and washed in 50 ml of CTC media. Tubes were centrifuged for 20 min at 200 g. After centrifugation, 25 ml of the supernatant was discarded carefully from each tube without disturbing cell pellets. An additional 25 ml of fresh CTC media was added, and tubes were centrifuged for an additional 5 min. All supernatant was removed except 24 ml of media at the bottom of each tube. Cells were pipetted up and down using 25 ml serological pipettes to obtain single cell suspensions. Cells were then plated on 4 two-well cyteslides (Rarecyte) at 3 ml/well and incubated for 30 min at 37°C . After incubation, slides were scanned for IM⁻/CSM⁺ cells (CTCs).

Negative selection staining. Buffy coats were stained with a cocktail of IM antibodies as described in the positive selection staining procedure and a live cell dye (LCD). Three LCDs were tested: DiO, Cell-Tracker green and ViaFluor. For both Cell-tracker green and DiO, cells were stained simultaneously with the IM antibodies cocktail for 30 min at 37°C . For ViaFluor, cells were stained first with Viafluor for 15 min then 1 ml of fresh media was added, and cells were incubated for 5 min at 37°C . After incubation, cells were centrifuged for 20 min at 200 g and the supernatant was removed. Cells were re-suspended in 1 ml of fresh media containing a cocktail of IM antibodies and incubated for 30 min at 37°C . After incubation, cells were washed, plated on cyteslides, and scanned using RareCyte.

Detection of CTCs. For both detection approaches, stained buffy coats were seeded on polyhema coated cyteslides and scanned semi-automatically using RareCyte fluorescence. Three ml of stained buffy coat was added to each chamber of the cyteslide. Slides were then incubated for 30 min at 37°C for cells to settle. Before cell retrieval, the ceramic tip (40 μ m) Rarecyte needle was primed and calibrated as previously described⁴¹. For positive selection, slides were scanned using the CSM fluorescent channel followed by IM channel to exclude the IM signal for the identified targets. For negative selection, slides were scanned using two fluorescent channels simultaneously.

Retrieval of live CTCs. When a CTC was detected, the needle was positioned right on top of the cell of interest with a 0.2 mm distance between the tip of the needle and the bottom of the slide. The cell was then drawn with a draw volume of 50 nL to 0.5 μ L, and the needle was moved to deposition position, where a PCR tube with 50 μ L of media had been placed. The needle was then moved down to a distance of 0.6 mm from the bottom of the tube and the cell was expelled down. PCR tubes were pulse spun and their contents were moved to a well of a 96 well GravityTRAP ultra low plate (InSphero).

Single-cell RNA-sequencing workflow. CTCs were spiked in healthy volunteers' blood and processed using AccuCyte. Buffy coats were prepared using positive selection protocol and scanned for CTCs using RareCyte fluorescence. Single CTCs and single immune cells were retrieved using RareCyte needle. Isolated single cells were processed using the SMARTer chemistry (SMART Seq v4 Ultra Low Input RNA Kit for Sequencing, Takara Clontech) according to manufacturer's instructions to generate single-cell cDNA libraries for mRNA sequencing. All cDNA samples were run on a TapeStation system (High Sensitivity D5000 DNA Analysis Kit as per manufacturer's protocol). cDNA libraries were prepared using the Nextera XT DNA Library Prep Kit (Illumina) with Nextera index kit index 1 (i7) and index 2 (i5) adapters. Libraries were sequenced on an Illumina NextSeq. 500 to obtain 75 bp-long single-end reads.

RNA-sequencing reads were trimmed for Nextera and Illumina adapter sequences using Trim Galore under default parameters. Trimmed reads were then mapped to the human genome build GRCh37 from Ensembl (ftp://ftp.ensembl.org/pub/grch37/current/fasta/homo_sapiens/dna/Homo_sapiens.GRCh37.dna_sm.primary_assembly.fa.gz) using STAR under optimized parameters for single-end sequenced data. Aligned reads were then counted via featureCounts⁵⁵ and piped into DESeq. 2⁵⁶ for normalization to sequencing depth and downstream analysis. For purposes of producing the PCA plot, count data was transformed via the vst function to eliminate the experiment-wide trend of variance over mean and the plot was produced using ggplot2. The contrast function was used to compare all samples under the Cell Type category “CTC” to samples under the “Immune cell” category and vice versa. Genes with a False Discovery Rate (FDR) of 0.05 and log₂ fold change of >2 were piped into IPA to predict function of each cell group.

Ex vivo culture of single CTCs. Single CTCs were cultured in GravityTRAP ultralow 96 well plates in CTC media at 37 °C, 5% CO₂ and 4% O₂ for 3 weeks. Media was replaced every 3–4 days and cells were counted every week. Proliferation rates of single cell clones were calculated as number of cells at a specific time point divided by that at the previous time point for each clone.

Statistical analyses. Statistical analysis was performed using GraphPad Prism (version 8.2.0). Data are represented as mean ± SEM. Data distribution was tested using the Shapiro-wilk test. If data were normally distributed, statistical significance was measured using parametric testing, with standard independent samples t-tests. If data were not normally distributed, non-parametric Mann-whitney U test was used to assess the difference between test and control samples. Differences were considered statistically significant if the probability value (p) was ≤0.05.

Data availability

RNA sequencing data is available upon request following publication.

Received: 8 May 2019; Accepted: 7 November 2019;

Published online: 25 November 2019

References

- Seyfried, T. N. & Huysentruyt, L. C. On the origin of cancer metastasis. *Critical reviews in oncogenesis* **18**, 43–73 (2013).
- Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. *Nature reviews. Cancer* **9**, 274–284, <https://doi.org/10.1038/nrc2622> (2009).
- Cristofanilli, M. *et al.* Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *The New England journal of medicine* **351**, <https://doi.org/10.1056/NEJMoa040766> (2004).
- Andreopoulou, E. & Cristofanilli, M. Circulating tumor cells as prognostic marker in metastatic breast cancer. *Expert review of anticancer therapy* **10**, 171–177, <https://doi.org/10.1586/era.09.105> (2010).
- Cristofanilli, M. *et al.* Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. *J Clin Oncol.* **23**, <https://doi.org/10.1200/jco.2005.08.140> (2005).
- Horton, C. E. *et al.* Circulating Tumor Cells Accurately Predicting Progressive Disease After Treatment in a Patient with Non-small Cell Lung Cancer Showing Response on Scans. *Anticancer research* **38**, 1073–1076, <https://doi.org/10.21873/anticancer.12325> (2018).
- Joesse, S. A., Gorges, T. M. & Pantel, K. Biology, detection, and clinical implications of circulating tumor cells. *EMBO molecular medicine* **7**, <https://doi.org/10.15252/emmm.201303698> (2015).
- Miller, M. C., Doyle, G. V. & Terstappen, L. W. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. *Journal of oncology* **2010**, 617421, <https://doi.org/10.1155/2010/617421> (2010).
- Alix-Panabieres, C., Schwarzenbach, H. & Pantel, K. Circulating tumor cells and circulating tumor DNA. *Annual review of medicine* **63**, 199–215, <https://doi.org/10.1146/annurev-med-062310-094219> (2012).
- Sollier, E. *et al.* Size-selective collection of circulating tumor cells using Vortex technology. *Lab on a chip* **14**, 63–77, <https://doi.org/10.1039/c3lc50689d> (2014).
- Kling, J. Beyond counting tumor cells. *Nature biotechnology* **30**, 578–580, <https://doi.org/10.1038/nbt.2295> (2012).
- Paterlini-Brechot, P. & Benali, N. L. Circulating tumor cells (CTC) detection: clinical impact and future directions. *Cancer letters* **253**, 180–204, <https://doi.org/10.1016/j.canlet.2006.12.014> (2007).
- Sun, Y. F. *et al.* Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. *Journal of cancer research and clinical oncology* **137**, 1151–1173, <https://doi.org/10.1007/s00432-011-0988-y> (2011).
- Witzig, T. E. *et al.* Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. *Clinical cancer research: an official journal of the American Association for Cancer Research* **8**, 1085–1091 (2002).
- Allard, W. J. *et al.* Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases. *Clinical Cancer Research* **10**, 6897–6904, <https://doi.org/10.1158/1078-0432.ccr-04-0378> (2004).
- Kamal M, Razaq W, Leslie M, Adhikari S & Tanaka, A. T. In *Breast Cancer - From Biology to Medicine* (ed. Phuc Van Pham) (IntechOpen, 2017).
- Laget, S. *et al.* Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion. *PLoS one* **12**, e0169427, <https://doi.org/10.1371/journal.pone.0169427> (2017).
- Li, W. *et al.* Biodegradable nano-films for capture and non-invasive release of circulating tumor cells. *Biomaterials* **65**, 93–102, <https://doi.org/10.1016/j.biomaterials.2015.06.036> (2015).
- Song, J. *et al.* DNA hydrogel delivery vehicle for light-triggered and synergistic cancer therapy. *Nanoscale* **7**, 9433–9437, <https://doi.org/10.1039/c5nr00858a> (2015).
- Sheng, W. *et al.* Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. *Lab on a chip* **14**, 89–98, <https://doi.org/10.1039/c3lc51017d> (2014).
- Ozkumur, E. *et al.* Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. *Science translational medicine* **5**, 179ra147, <https://doi.org/10.1126/scitranslmed.3005616> (2013).
- Yu, M. *et al.* Cancer therapy. *Ex vivo* culture of circulating breast tumor cells for individualized testing of drug susceptibility. *Science* **345**, 216–220, <https://doi.org/10.1126/science.1253533> (2014).
- Yu, M. *et al.* Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. *Science* **339**, 580–584, <https://doi.org/10.1126/science.1228522> (2013).

24. Theodoropoulos, P. A. *et al.* Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. *Cancer letters* **288**, <https://doi.org/10.1016/j.canlet.2009.06.027> (2010).
25. Wang, J. *et al.* A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer. *Cellular and molecular biology* **58**(Suppl), OL1641–1645 (2012).
26. Baccelli, I. *et al.* Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. *Nature biotechnology* **31**, <https://doi.org/10.1038/nbt.2576> (2013).
27. Papadaki, M. A. *et al.* Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. *BMC cancer* **14**, 651, <https://doi.org/10.1186/1471-2407-14-651> (2014).
28. Polioudaki, H. *et al.* Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. *BMC cancer* **15**, 1–10, <https://doi.org/10.1186/s12885-015-1386-7> (2015).
29. Bulfoni, M. *et al.* In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. *Breast Cancer Research* **18**, 1–15, <https://doi.org/10.1186/s13058-016-0687-3> (2016).
30. Powell, A. A. *et al.* Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. *PLoS one* **7**, e33788, <https://doi.org/10.1371/journal.pone.0033788> (2012).
31. Jordan, N. V. *et al.* HER2 expression identifies dynamic functional states within circulating breast cancer cells. *Nature* **537**, 102–106, <https://doi.org/10.1038/nature19328> (2016).
32. Aceto, N. *et al.* Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. *Cell* **158**, 1110–1122, <https://doi.org/10.1016/j.cell.2014.07.013> (2014).
33. Aceto, N., Toner, M., Maheswaran, S. & Haber, D. A. En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition. *Trends in cancer* **1**, 44–52, <https://doi.org/10.1016/j.trecan.2015.07.006> (2015).
34. Polzer, B. *et al.* Molecular profiling of single circulating tumor cells with diagnostic intention. *EMBO molecular medicine* **6**, 1371–1386, <https://doi.org/10.15252/emmm.201404033> (2014).
35. Di Trapani, M., Manaresi, N. & Medoro, G. DEPArray™ system: An automatic image-based sorter for isolation of pure circulating tumor cells. *Cytometry Part A* **93**, 1260–1266, <https://doi.org/10.1002/cyto.a.23687> (2018).
36. DeLaughter, D. M. The Use of the Fluidigm C1 for RNA Expression Analyses of Single Cells. *Current protocols in molecular biology* **122**, e55, <https://doi.org/10.1002/cpmb.55> (2018).
37. Durruthy-Durruthy, R. & Ray, M. Using Fluidigm C1 to Generate Single-Cell Full-Length cDNA Libraries for mRNA Sequencing. *Methods in molecular biology* **1706**, 199–221, https://doi.org/10.1007/978-1-4939-7471-9_11 (2018).
38. Gong, H., Do, D. & Ramakrishnan, R. Single-Cell mRNA-Seq Using the Fluidigm C1 System and Integrated Fluidics Circuits. *Methods in molecular biology* **1783**, 193–207, https://doi.org/10.1007/978-1-4939-7834-2_10 (2018).
39. Xin, Y. *et al.* Use of the Fluidigm C1 platform for RNA sequencing of single mouse pancreatic islet cells. *Proceedings of the National Academy of Sciences of the United States of America* **113**, 3293–3298, <https://doi.org/10.1073/pnas.1602306113> (2016).
40. Nelep, C. & Eberhardt, J. Automated rare single cell picking with the ALS cellselector. *Cytometry. Part A: the journal of the International Society for Analytical Cytology* **93**, 1267–1270, <https://doi.org/10.1002/cyto.a.23568> (2018).
41. Campion, D. E. *et al.* High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. *BMC cancer* **15**, 360, <https://doi.org/10.1186/s12885-015-1383-x> (2015).
42. Kaldjian, E. P. *et al.* The RareCyte(R) platform for next-generation analysis of circulating tumor cells. *Cytometry. Part A: the journal of the International Society for Analytical Cytology* **93**, 1220–1225, <https://doi.org/10.1002/cyto.a.23619> (2018).
43. Szczerba, B. M. *et al.* Neutrophils escort circulating tumour cells to enable cell cycle progression. *Nature* **566**, 553–557, <https://doi.org/10.1038/s41586-019-0915-y> (2019).
44. Stott, S. L. *et al.* Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. *Proceedings of the National Academy of Sciences* **107**, 18392–18397, <https://doi.org/10.1073/pnas.1012539107> (2010).
45. Marrinucci, D. *et al.* Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. *Physical biology* **9**, 10.1088/1478-3975/9/1/016003 (2012).
46. Meye, A. *et al.* Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. *International journal of oncology* **21**, 521–530 (2002).
47. Kang, H., Kim, J., Cho, H. & Han, K.-H. Evaluation of Positive and Negative Methods for Isolation of Circulating Tumor Cells by Lateral Magnetophoresis. *Micromachines (Basel)* **10**, 386, <https://doi.org/10.3390/mi10060386> (2019).
48. Wang, X. *et al.* Microfluidic chip combined with magnetic-activated cell sorting technology for tumor antigen-independent sorting of circulating hepatocellular carcinoma cells. *PeerJ* **7**, e6681–e6681, <https://doi.org/10.7717/peerj.6681> (2019).
49. Kallergi, G., Politaki, E., Alkahtani, S., Stournaras, C. & Georgoulas, V. Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs). *Cellular Physiology and Biochemistry* **40**, 411–419, <https://doi.org/10.1159/000452556> (2016).
50. Wu, S. *et al.* In *Clinical Chemistry and Laboratory Medicine (CCLM)* Vol. 52 243 (2014).
51. Warkiani, M. E. *et al.* Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. *Lab on a chip* **14**, 128–137, <https://doi.org/10.1039/c3lc50617g> (2014).
52. Lapin, M. *et al.* Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells. *BMC cancer* **17**, 390, <https://doi.org/10.1186/s12885-017-3385-3> (2017).
53. Bertolini, F., Shaked, Y., Mancuso, P. & Kerbel, R. S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. *Nature Reviews Cancer* **6**, 835–845, <https://doi.org/10.1038/nrc1971> (2006).
54. Xu, L. & Li, G. Circulating mesenchymal stem cells and their clinical implications. *Journal of Orthopaedic Translation* **2**, 1–7, <https://doi.org/10.1016/j.jot.2013.11.002> (2014).
55. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923–930, <https://doi.org/10.1093/bioinformatics/btt656> (2014).
56. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq. 2. *Genome biology* **15**, 550, <https://doi.org/10.1186/s13059-014-0550-8> (2014).

Acknowledgements

We thank RareCyte for their technical support and providing reagents required for the development of this assay. This research was supported by the following: The National Institutes of Health (NIH) grants DP2 CA206653 (M.Y.) and T190 T90DE021982 (Y.A.), the Stop Cancer Foundation (M.Y.), the PEW Charitable Trusts and the Alexander & Margaret Stewart Trust (M.Y.), the Merkin Family Foundation (M.Y.), and the CIRM Bridges award EDUC2-08381 to CSU, Channel Islands (intern S.S.). M.Y. is a Pew-Stewart Scholar for Cancer Research and a Richard N. Merkin Assistant Professor. The project described was supported by award number P30CA014089 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Author contributions

M.Y. and O.I. generated the idea of the assay. M.Y. edited and provided final approval of the manuscript, M.K. and S.S. performed experiments. M.K. wrote the manuscript. O.I. and R.K. contributed to the optimization of the system. Y.A. analyzed RNA sequencing data. Y.C., V.T, J.E.L. and I.K. recruited patient samples and analyzed clinical data. O.I., R.K., Y.A. and J.E.L edited the manuscript. All authors reviewed the manuscript.

Competing interests

M.Y. is the founder and president of CanTraCer Biosciences Inc. J. E. L. received research support from ANGLE Parsortix and is on the speaker bureau of Genomic Health. I. K. is on the speaker bureau of Puma Biotechnology. Other authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-019-53899-4>.

Correspondence and requests for materials should be addressed to M.Y.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019